Is AbbVie Stock Really Expensive?

For questions about this article or underlying research, email help@trefis.com.

AbbVie (ABBV) stock trades at 50.4 times its earnings over the past twelve months, compared with 21.9 times for the S&P 500. Anyone buying at that multiple is paying now for profit AbbVie has yet to report, and the business has to grow into its price. So how fast would AbbVie have to grow just for today’s share price to hold?

AbbVie Would Have To Outgrow Its Current Pace

At its current price, AbbVie would need to grow revenue about 16.6% a year for five years merely to maintain its share price, offering no return on top. Over the four quarters ended September 30, 2026, its revenue grew 10.7%. The years, the mature P/E and the steady net margin are Trefis assumptions.

AbbVie’s market value was $521 billion at the November 12, 2026 close. At a mature P/E of 22.8, that value would mean annual net income of $22.8 billion. At a steady net margin of 16.1%, that profit would take revenue of $142 billion by fiscal Q3 2031. That margin is just above AbbVie’s best twelve-month net margin of 15.7% over the last twelve quarter-ends, and well above the 8.5% average over that span. The revenue needed is more than double the $66.0 billion AbbVie reported over the past twelve months. Trefis allows five years because today’s P/E is more than twice the mature one.

Trefis built the mature P/E mostly from the 18.0 level it uses for pharmaceuticals and biotechnology companies, with a 40% weight on AbbVie’s own average. That average was 81.0 over the last twelve quarter-ends. Trefis caps any company average above 30 at 30, so AbbVie’s average counts only as 30.

Does AbbVie’s Outlook Support That Pace Of Growth?

Not so far. Management expects revenue of about $67.8 billion for fiscal 2026, against the $61.2 billion AbbVie reported for fiscal 2025, it said on the October 30, 2026 call. That is growth of about 10.8%, near today’s pace, and only fiscal Q4 2026, the last quarter of that guided year, falls inside the five years. Management will give 2027 guidance on its fourth-quarter call.

The immunology drugs Skyrizi and Rinvoq are the two largest drugs in the guidance. Skyrizi sold $17.6 billion in fiscal 2025, and management expects $21.8 billion for fiscal 2026; Rinvoq sold $8.3 billion in fiscal 2025, and management expects $10.3 billion for fiscal 2026. Both have to make up for Humira, whose sales fell 49.5% in fiscal 2025.

How Firm Is AbbVie’s Growth Requirement?

The requirement depends most on the years allowed. If AbbVie’s P/E settled to the mature level in three years, the company would have to grow revenue 29.2% a year. Given seven years, it would need 11.6%. So how expensive AbbVie looks depends on how long you expect its multiple to stay high.

AbbVie is also starting from its best recent figures. Its revenue growth over the past twelve months was its fastest of the last five twelve-month periods, and its twelve-month net margin was 4.0% a year earlier. The requirement assumes AbbVie keeps its net margin a little above its recent high and lifts revenue growth well above its recent pace.

Based on today’s figures, AbbVie stock is expensive: the business would have to grow faster than in any recent year simply for the price to hold. Achieving that pace requires Skyrizi and Rinvoq to grow fast enough to more than replace Humira, with the net margin kept near its recent high. If revenue growth slips back to its earlier pace, AbbVie would need more years, and the stock becomes a riskier bet. AbbVie’s revenue guidance for 2027, due on its fourth-quarter call, is the number to watch.

Does This Mean You Should Act On ABBV?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.

Spot an error or want more like this? Tell us in 10 seconds.